The SEC comment letter and amendment signal heightened regulatory scrutiny of RenovoRx's internal controls. While the weaknesses were remediated, the disclosure suggests the SEC found the original 10-K's controls discussion inadequate. Monitor for any follow-up SEC inquiries or further amendments. The company expects TIGeR-PaC Phase III enrollment completion by mid-2026 and final data readout in 2027 — these are the primary catalysts.
Price Chart
Executive Summary
RenovoRx filed Amendment No. 1 to its 2025 10-K solely to revise risk factor disclosures (Item 1A) and add missing controls-and-procedures disclosure (Item 9A) in response to an SEC staff comment letter. The amendment clarifies previously identified material weaknesses in internal control over financial reporting that were remediated as of December 31, 2025, and adds management's assessment that internal controls were effective at year-end. No financial restatements, auditor changes, or new financial data are included.
Key Facts
- Amendment filed May 15, 2026 in response to SEC staff comment letter on the original 10-K filed March 30, 2026
- Only Items 1A (Risk Factors) and 9A (Controls and Procedures) were amended; no financial statements restated
- Disclosed that material weaknesses in internal control over financial reporting were remediated as of December 31, 2025
- Management's conclusion that internal control over financial reporting was effective at December 31, 2025 remains unchanged
- New CEO/CFO certifications (Exhibits 31.1, 31.2, 32.1, 32.2) filed with the amendment
- Accumulated deficit of approximately $61.4 million as of December 31, 2025; net losses of $11.2M (2025) and $8.8M (2024)
Financial Impact
No financial restatement; accumulated deficit $61.4M, net loss $11.2M in 2025, revenue $1.1M from RenovoCath sales in 2025
Risk Factors
- SEC scrutiny may continue if additional disclosure gaps are identified
- Going concern risk remains: $13.0M cash as of March 23, 2026; needs additional capital for IAG development and RenovoCath commercialization
- Nasdaq minimum bid price compliance risk — stock trading near $0.86 vs. $1.00 minimum
- Phase III TIGeR-PaC trial failure would be material adverse event
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001193125-26-227256 |
| Document: 0001193125-26-227256-index.html | 0001193125-26-227256 |
| Document: 0001193125-26-227256.txt | 0001193125-26-227256 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $1.27 | awaiting T+60 | — | $1.31 (+3.15%) |
Jul 29, 2026 12w ago | Press Release | $0.8981 $1.27 | ▲ +41.41% | ▲ +36.68% | $1.31 (+45.86%) |
Jul 2, 2026 16w ago | 8-K | $0.9201 $1.68 | ▼ −82.59% | ▼ −79.58% | $1.31 (−42.38%) |
May 26, 2026 22w ago | Press Release | $0.9160 $1.32 | ▲ +43.56% | ▲ +40.83% | $1.31 (+43.01%) |
May 19, 2026 23w ago | Press Release | $0.8060 $1.26 | ▲ +56.33% | ▲ +50.04% | $1.31 (+62.53%) |
May 15, 2026 23w ago | 10-K/A | $0.7830 $1.12 | ▲ +43.04% | ▲ +38.19% | $1.31 (+67.31%) |
May 14, 2026 23w ago | 8-K | $0.8200 $1.15 | ▲ +40.24% | ▲ +35.73% | $1.31 (+59.76%) |
Apr 29, 2026 25w ago | Press Release | $0.8310 $0.8653 | ▲ +4.13% | ▲ +0.02% | $1.31 (+57.64%) |
Apr 28, 2026 26w ago | EFFECT | $0.8400 $0.8545 | ▲ +1.73% | ▼ −2.26% | $1.31 (+55.95%) |
Apr 16, 2026 27w ago | S-3 | $1.00 $0.8500 | ▼ −15.00% | ▼ −21.14% | $1.31 (+31.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers